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Bradykinin and related kinins have been implicated in the initiation and maintenance of intlammation. Cytokines appear 
to be the primary mediators of many inflammatory diseases. The potential ability of bradykinin to stimulate release of 
tumor necrosis factor and interleukin-1 from macrophages was examined. Bradykinin stimulated release of both cyto- 
kines from P388-Dl and RAW264.7 murine macrophages. Studies with selective agonists and antagonists uggest hat 
cytokine release is mediated by a B, kinin receptor. 
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1. INTRODUCTION 
Multiple mediators appear to play roles in the 
pathogenesis of chronic inflammation. Macro- 
phages and lymphocytes interact to release a varie- 
ty of inflammatory cytokines, including tumor 
necrosis factor (TNF) and interleukin-1 (IL-l) 
which induce proliferation of connective tissue and 
stimulate eicosanoid and proteolytic enzyme 
release [ 11. 
Bradykinin, unlike many other biologically ac- 
tive peptides, is synthesized at the site of its action 
by plasma or tissue kallikrein, acting on several cir- 
culating kininogen substrates [2]. It is rapidly 
degraded at its site of action by kininases, prin- 
cipally by circulating kininase I, which yields 
desArg’bradykinin [3], and in some tissues by 
kininase II, which cleaves the 2 carboxy-terminal 
residues [3]. Several ines of evidence suggest a role 
for bradykinin and related kinins in the generation 
and maintenance of chronic inflammation. All 
components of the kinin system: kininogens, 
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kallikrein, and kinins, have been reported from in- 
flammatory effusions [3]. 
In at least some instances, certain kininogen 
substrates are among the acute phase proteins in- 
duced by inflammatory cytokines [4]. Kinins 
reproduce several inflammatory processes also in- 
duced by cytokines including increased capillary 
permeability, stimulation of eicosanoid synthesis 
and induction of connective tissue proliferation 
[3]. We now report that bradykinin and desArg’- 
bradykinin stimulate macrophages to release TNF 
and IL-l. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
SV-T2 fibroblasts (ACTCC CCL 163.1), 3T3-Ll adipocytes 
(ATCC CCL 92.1), P388-Dl macrophages (ATCC TIB 63) and 
RAW264.7 macrophages (ATCC TIB 71) obtained from the 
American Type Culture Collection were maintained as previous- 
ly described [S-8]. 
2.2. Stimulation protocol 
Macrophages were washed once with serum-free medium. 
Then serum-free medium containing the kinin analog was add- 
ed, and incubation continued for 24 h. Supernatants were col- 
lected, centrifuged to remove any cells, and calf serum was add- 
ed to 10% final concentration to degrade bradykinin [9]. High- 
pressure liquid chromatography was used to confirm that all 
bradykinin was degraded [9]. 
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2.3. Kinin analogs 
Both IL-l [5] and TNF [lo] stimulate prostaglandin Ez (PGE) 
synthesis in SV-TZ fibroblasts. Dose responses for various kinin 
agonists and antagonists on fibroblast PGE synthesis were 
determined by radioimmunoassay of PGE in fibroblast super- 
natants as described [5]. Fibroblasts were incubated with serum- 
repleted macrophage supernatants for 24 h. 
2.4. IL-1 activity 
IL-l activity was measured as the ability to stimulate 
[3H]thymidine incorporation in thymocytes [111. Activity in the 
cell supernatants was quantitated by comparing the ability of 
serial dilutions of supernatant to stimulate [“Hlthymidine incor- 
poration with standard concentrations of recombinant IL-l. 
2.5. TNF activity 
TNF completely inhibits lipoprotein lipase activity in 3T3-Ll 
cells [12]. Activity in the cell supernatants was quantitated by 
comparing the ability of serial dilutions of supernatant to inhibit 
lipoprotein lipase with recombinant murine TNF. 
2.6. Labeling of macrophage proteins 
Macrophage culture media were supplemented with 
[t4C]valine or [35S]methionine, then kinins added for 24 h. 
Media were collected, filtered through 0.2 pM membranes to 
remove cells, and concentrated by ultrafiltration through 10 
kDa cut-off membranes (Amicon, Danvers, MA). The concen- 
trated supernatants were subjected to 12% polyacrylamide gel 
electrophoresis in SDS [13], silver stained (BioRad), dried and 
subjected to autoradiography. 
2.1. Materials 
Bradykinin, desArg%adykinin was obtained from Nova 
Pharmaceutical Corporation. Recombinant human IL-la, 
recombinant murine TNF, and anti-murine TNF were obtained 
from Genzyme, Boston, MA. 
2.8 Statistical analyses 
Experiments were run in multi-well plates. Comparison were 
thus made using Student’s t-test for paired observations con- 
sidering the 3 triplicate wells for each manipulation in a single 
plate as one observation. 
3. RESULTS 
3.1. Kinins stimulate cytokine release from 
macrophages 
When 24-h macrophage supernatants were 
serum-repleted and added to SV-TZ cells, PGE syn- 
thesis was stimulated. For example, in 5 experi- 
ments, control PGE synthesis was 1 .l f 0.5 
ng/ml. Addition of P388-Dl supernatant caused 
PGE synthesis to increase to 11.2 f 3.6 ng/ml, 
and when bradykinin (10 PM) had been added to 
the macrophages, PGE synthesis further increased 
to 31.0 + 17.7 ng/ml. If macrophages had been 
incubated with bradykinin-free media, then media 
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collected and bradykinin plus serum added to 
degrade it, the degradation products of bradykinin 
did not affect PGE synthesis. The increased PGE 
synthesis in the absence of bradykinin represents 
cytokine released basally in these cells [7] since 
anti-TNF serum blocked basal and bradykinin- 
stimulated activity (see below). 
Bradykinin receptors are divided into 2 main 
subtypes, Br and B2 [14]. In additional experiments 
(table l), it was found that the Bi-selective agonist 
desArggbradykinin stimulated cytokine release as 
well as bradykinin, and the mixed Bi/B2 antagonist 
DArg[Hyp’DPhe’]bradykinin [2] and the Bi-se- 
lective antagonist desArgg[Leu8]bradykinin [ 141 
blocked kinin-induced cytokine release. A similar 
pattern was observed when another macrophage 
line, RAW264.7, was used (data not shown). 
3.2. Kinins stimulate release of 17 kDa proteins 
selectively 
When bradykinin was added to macrophages in 
the presence of [‘4C]valine or [35S]methionine and 
supernatants collected, it was found that the kinin 
rather selectively caused release into the media of 
protein(s) of about 17 kDa (fig.1). 
3.3. Kinins stimulate TNF release 
Both TNF and IL-1 inhibit lipoprotein lipase in 
3T3-Ll cells [12], but IL-1 is able to inhibit about 
Table 1 
Kinins release cytokine activity from P388-Dl macrophage 
Treatment 
Bradykinin (1 ,uM) 
Bradykinin (100 PM) 
Bradykinin (100 PM) 
PGE (070 of control) 
130 + 5oa 
187 + 32b 
+ DArg[Hyp3DPhe7]brady- 
kinin (1 mM) 
Bradykinin (100 ,uM) 
89 * 18a 
+ desArg’[Leu*]bradykinin 
(1OOpM) 138 f 13’ 
desArg%adykinin (1 CM) 118 + 36” 
desArg6bradykinin (100 FM) 223 + 70b 
desArg%radykinin (100 PM) 
+ desArg’[Leu’]bradykinin 
(100 PM) 147 + 27’ 
a Not significantly different from control 
b P< 0.05 compared to control 
’ P~0.05 compared to agonist 
Mean + SE for 3 experiments. Neither DArg[Hyp’DPhe’]- 
bradykinin nor desArg’[Leu*]bradykinin had any effect by 
themselves at concentrations up to 1 mM 
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Fig. 1. Bradykinin stimulates release of 17 kDa protein(s) from 
P388-Dl macrophages. Cells were labeled with [3SS]methionine 
for 24 h in the presence (BK) or absence (control) of 10,4M 
bradykinin. The proteins released into the supernatant were pro- 
cessed (section 2) and subjected to polyacrylamide gel elec- 
trophoresis in the presence of 2-mercaptoethanol. Gels were 
dried and subjected to autoradiography. Values on the left in- 
dicate migration of marker proteins (kDa). 
50% of the activity while TNF is able to completely 
inhibit activity [ 121. We confirmed this finding us- 
ing recombinant TNF and IL-l (data not shown). 
P388-Dl macrophage supernatant completely in- 
hibited lipoprotein lipase activity. Quantitation of 
TNF release using serial dilutions of macrophage 
supernatant revealed that bradykinin increased 
TNF release 6-fold (table 2A). That the cytokine 
released was primarily TNF is supported by the 
observation that anti-TNF largely neutralized by 
Table 2 
Kinins stimulate release of TNF and IL-l from macrophages 
Treatment TNF (pmol/well) IL-1 @mol/well) 
A. Kinin-stimulated cytokine concentrations 
Control 0.5 * 0.1 0.034 f 0.012 
Bradykinin (10 FM) 2.6 f 0.15 0.076 f 0.015 
desArg%adykinin 
(10 /rM) - 0.082 f 0.022 
Lipoprotein lipase 
(nmol/min per well) 
B. Anti-TNF neutralizes macrophage cytokine activity 
Control 4.30 
P388-Dl media 2.05 
P388-Dl media + 1:500 anti-TNF 1.98 
P388-Dl media + 1:125 anti-TNF 2.59 
P388-Dl media + 1:62.5 anti-TNF 3.64 
In all experiments P388-Dl macrophages were grown in 24-well 
plates. n = 2-5 for A; a representative experiment (among 3 ex- 
periments) is shown for B. Macrophage media was incubated 
with assay cells for 3 days (IL-l) or 24 h (TNF) 
the ability of the macrophage supernatant o in- 
hibit lipoprotein lipase (table 2B). In control ex- 
periments the antibody was found to neutralize 
authentic TNF without affecting authentic IL-1 
(data not shown). 
3.4. Kinins stimulate IL-I release 
Using a thymocyte activation assay, bradykinin 
was found to stimulate release of IL-l activity 
(table 2A). In this assay, we found that desArg’- 
bradykinin added directly to the thymocyte assay 
could itself stimulate thymidine incorporation to 
about 20% the level of bradykinin- or desArg’- 
bradykinin-incubated macrophage supernatant, 
confirming an earlier finding [ 151. This activity was 
subtracted from the values in table 2A. 
4. DISCUSSION 
The present study demonstrates that kinins 
stimulate cytokine release from macrophages. 
Analog studies suggest that a Br kinin receptor 
mediates the effect. The stimulation was rather 
selective in that by electrophoresis, proteins of 17 
kDa were increased predominantly, the molecular 
mass of both TNF and IL-l. The release of TNF 
was stimulated to a far greater extent than brady- 
kinin (table 2A). 
Bradykinin is generated at inflammatory sites in- 
191 
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eluding rheumatoid joints [2]. Bradykinin acts on 
Br and BZ receptors, being much more potent at Bz 
receptors [141. A major metabolic degradation pro- 
duct, desArggbradykinin is a selective agonist for 
the Bi receptor [14]. Thus, the presence of Br 
receptors on macrophages that stimulate cytokine 
release, suggests that kinins may be significant 
stimulators of TNF and IL-l release in inflam- 
matory lesions. Further work will be required to 
test this hypothesis in vivo. 
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